Bruker Corporation (BRKR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,988 | 2,418 | 2,531 | 2,965 | 3,366 | 3,437 | 3,500 | 3,557 |
| Operating profit | $m | 236 | 127 | ||||||
| Net profit | $m | 158 | 277 | 297 | 427 | 113 | -9 | -71 | 326 |
| EPS reported | $ | -0.06 | -0.70 | ||||||
| Operating cashflow per share | $ | 0.88 | 1.25 | ||||||
| Capex per share | $ | 0.79 | 0.63 | ||||||
| FCF per share | $ | 0.09 | 0.62 | ||||||
| Free cash flow | $m | 14 | 94 | ||||||
| Net debt | $m | 1,448 | 1,731 | ||||||
| Book value equity | $m | 2,457 | 2,400 | ||||||
| Book value per share | $ | 16.18 | 15.77 | ||||||
| Number of shares | m | 151.8 | 152.2 | ||||||
| DPS (TTM paid) | $ | 0.20 | 0.20 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.91 | 2.98 | ||||||
| P/S LTM | x | 2.08 | 2.04 | ||||||
| P/FCF LTM | x | 514.48 | 76.16 | ||||||
| EV/EBITDA LTM | x | 29.40 | 35.91 | ||||||
| EV/Sales LTM | x | 2.59 | 3.04 | ||||||
| Earnings Yield LTM | % | -0.12% | -0.80% | ||||||
| FCF Yield | % | +0.19% | +1.31% | ||||||
| Quality | |||||||||
| ROE | % | -0.35% | -2.92% | ||||||
| ROIC | % | -1.86% | +2.56% | ||||||
| Operating margin | % | +6.87% | +3.61% | ||||||
| Gross margin | % | +45.91% | +46.69% | ||||||
| FCF/Sales | % | +0.40% | +2.68% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +2.08% | +3.96% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -89.78% | -30.96% | ||||||
| Operating Profit Growth | % | -6.76% | -50.02% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.32% | +0.34% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | -100.13% | -51.37% | ||||||
| FCF/Debt | x | 0.01 | 0.05 | ||||||
| Net Debt/EBITDA | x | 5.76 | 6.99 | ||||||
| EBIT/Net interest | x | 3.91 | 2.89 | ||||||
| Net debt/market cap | % | +24.42% | +21.51% | ||||||
| Net debt/Equity | x | 0.59 | 0.72 | ||||||
| Gross debt/equity | x | 0.83 | 0.80 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free